Strategic Partnership Proposal: Building Dallas's Premier Cardiovascular ASC

This proposal outlines an equity partnership between Greg Hackney's ASC company and Dr. Pedro Martinez-Clark's amavita Heart and Vascular Health® to create Dallas's premier cardiovascular ambulatory surgery center. As a Harvard-trained interventional cardiologist with proven success in Miami, Dr. Martinez-Clark seeks a minority stake to serve as Medical Director while leveraging Greg's existing ASC infrastructure for cardiovascular procedures.


By amavita Heart and Vascular Health®

July 14, 2025

Market Opportunity: A $55+ Billion Growth Story

$55B

U.S. Cardiology Market

The U.S. cardiology procedures market reached $55.0 billion in 2023

7.9%

Annual Growth

Projected CAGR through 2033

66%

ASC-Eligible

Of cardiac catheterization procedures can be performed in ASC settings

Dallas presents particularly attractive conditions with a cardiovascular disease death rate of 435.1 per 100,000 (above national average), 2.6+ million residents, and favorable payer mix with $71,000 median household income. As a non-CON state, Texas provides a favorable regulatory environment with 608 licensed ASCs representing 42% growth since 2019.

Dr. Pedro Martinez-Clark: Proven Track Record

Clinical Credentials

  • Harvard-trained interventional cardiologist with 27+ years experience
  • Board certified in Internal Medicine, Cardiovascular Disease, and Interventional Cardiology
  • 12,000+ minimally invasive procedures performed
  • Fellowship at Beth Israel Deaconess Medical Center/Harvard

Business Success

  • Founded amavita Heart and Vascular Health® in 2017
  • Opened 15,000 sq ft cardiovascular ASC in Miami
  • Launched 20,000 sq ft Aventura Medical Tower Surgery Center
  • AISAP Technology Pioneer implementing AI-powered diagnostics

Proposed Partnership Structure

Ownership Structure

  • Greg Hackney/Current Group: [TBD%] (majority control)
  • Dr. Pedro Martinez-Clark: [TBD%] (minority stake)
  • Additional investors: 10-15% (optional)

Integrated Revenue Centers

  • Clinic for patient intake and management
  • Advanced cardiovascular imaging
  • PET using Ammonia (NH3)
  • Clinical research program


Key Financial Highlights

Accelerated Break-even

Positive EBITDA now expected midway through 2026, over a year ahead of the prior model's projection.

Sustained Compound Growth

Revenue continues to scale at a ~90% CAGR from 2025-2027, driven by strategic initiatives.

Optimized Capacity Utilization

Projected 1,800 annual procedures by Year 3, reaching ~65% utilization with headroom for growth.

ASC Retrofit and Service Development

Infrastructure Requirements

  • Hybrid operating suite with advanced imaging
  • Cardiac catheterization lab with Philips/GE C-arm
  • Recovery bay expansion for cardiovascular patients
  • Specialized equipment including IVUS, FFR systems

Implementation will follow a phased approach over 12 months, from partnership formation to facility launch.

1

Diagnostic Services

  • Cardiac catheterization
  • Peripheral angiography
  • Electrophysiology studies
2

Interventional Procedures

  • Percutaneous coronary interventions (PCI) with stent placement
  • Peripheral vascular interventions for claudication and critical limb ischemia
  • Pacemaker and defibrillator implantation
  • Structural heart procedures (future expansion opportunity)
  • Congestive heart failure procedures, including device implantation and monitoring
  • Interventional Radiology procedures for vascular and non-vascular conditions
  • Interventional Oncology procedures for tumor embolization and ablation
3

Patient Experience

  • Same-day procedures
  • Reduced wait times
  • Cost transparency

Integrated Additional Revenue Centers

Beyond the ASC, our strategic partnership will establish a comprehensive ecosystem of revenue-generating centers to create a fully integrated patient care model and maximize profitability:

Clinic

Our dedicated cardiology clinic will serve as the primary patient intake and management hub, offering consultations, diagnostic evaluations, and pre/post-procedure care. This ensures a consistent pipeline of high-value patients for the ASC and other service lines.

Imaging

We will incorporate advanced cardiovascular imaging capabilities, including echocardiography, vascular ultrasound, and potentially CT angiography, to provide comprehensive diagnostic services in-house. This enhances patient convenience and captures additional revenue streams.

PET using Ammonia (NH3)

The integration of a state-of-the-art PET imaging facility utilizing Ammonia (NH3) will allow for highly accurate and specialized myocardial perfusion imaging. This cutting-edge technology offers superior diagnostic capabilities for complex cardiovascular conditions, attracting high-acuity cases and establishing a premium service offering.

Clinical Research

Leveraging our collective expertise and patient volume, we will establish a robust clinical research program. Participation in clinical trials for new cardiovascular devices and therapies not only generates direct revenue through research grants and patient enrollment fees but also enhances our reputation as a leading-edge facility, attracting top talent and innovative procedures.

Strategic Advantages and Next Steps

Partnership Formation

Execute Letter of Intent, complete due diligence, refine market analysis, develop legal framework (Next 30 days)

Implementation

Execute definitive agreement, complete ASC retrofit planning, develop physician recruitment strategy (Next 90 days)

Launch

Facility renovation, staff recruitment, payer negotiations, marketing campaign, and operational optimization

This partnership leverages Greg's ASC operational expertise and local market presence with Dr. Martinez-Clark's cardiovascular excellence and proven business success. The cardiovascular ASC market is at a critical inflection point, positioning this venture to capture significant market share while providing exceptional patient care and generating substantial returns.